According to our estimates, Roche's autoimmune drug sales may peak in 2018, following which we expect a gradual decline due to patent losses and expected competition from biosimilars and generics.
According to our estimates, Roche's autoimmune drug sales may peak in 2018, following which we expect a gradual decline due to patent losses and expected competition from biosimilars and generics.
Share this Article
Recommended